L3VLUP
ProSign in

OLMA · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

OLMALLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • OLMA
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterOLMALLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 20202 holders, $173m29 holders, $17.3bn
Q1 20212 holders, $122m24 holders, $23.0bn
Q2 20212 holders, $97m24 holders, $27.8bn
Q3 20211 holders, $68m31 holders, $29.9bn
Q4 20211 holders, $1.8m31 holders, $34.7bn
Q1 2022none listed holders, n.a.24 holders, $35.3bn
Q2 2022none listed holders, n.a.33 holders, $42.7bn
Q3 2022none listed holders, n.a.31 holders, $43.4bn
Q4 2022none listed holders, n.a.31 holders, $46.6bn
Q1 2023none listed holders, n.a.33 holders, $44.3bn
Q2 20232 holders, $11m37 holders, $59.6bn
Q3 20233 holders, $15m44 holders, $67.6bn
Q4 20231 holders, $11m45 holders, $73.6bn
Q1 20241 holders, $8.5m41 holders, $95.3bn
Q2 20242 holders, $44m43 holders, $110bn
Q3 20242 holders, $60m45 holders, $107bn
Q4 20242 holders, $29m46 holders, $93.9bn
Q1 20251 holders, $5.6m42 holders, $98.4bn
Q2 20251 holders, $15m43 holders, $93.2bn
Q3 20252 holders, $57m39 holders, $86.7bn
Q4 20256 holders, $221m41 holders, $123bn
Q1 20263 holders, $128m39 holders, $106bn
Q2 20262 holders, $96m44 holders, $132bn
OLMA

Olema Pharmaceuticals Inc

Holders
1
Reported value
$8.5m
Buyers
0
Sellers
0

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$95.3bn
Buyers
15
Sellers
27

Breadth -12 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only OLMA (0)

None.

Only LLY (40)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, and 15 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →